dc.contributor.author |
Dombi P |
|
dc.contributor.author |
Illes A |
|
dc.contributor.author |
Demeter, Judit |
|
dc.contributor.author |
Homor L |
|
dc.contributor.author |
Simon Z |
|
dc.contributor.author |
Kellner A |
|
dc.contributor.author |
Karadi E |
|
dc.contributor.author |
Valasinyoszki E |
|
dc.contributor.author |
Udvardy M |
|
dc.contributor.author |
Egyed, Miklós |
|
dc.date.accessioned |
2018-08-09T10:16:06Z |
|
dc.date.available |
2018-08-09T10:16:06Z |
|
dc.date.issued |
2017 |
|
dc.identifier |
85020476020 |
|
dc.identifier.citation |
pagination=901-909;
journalVolume=158;
journalIssueNumber=23;
journalTitle=ORVOSI HETILAP; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/5824 |
|
dc.identifier.uri |
doi:10.1556/650.2017.30766 |
|
dc.description.abstract |
Intruduction and aim: The Hungarian National Registry for
Philadelphia chromosome negative myeloproliferative neoplasms
has been developed. The aim of the recent study is to assess
the clinical characteristics of Hungarian patients with
polycythemia vera. METHOD: Data of 351 JAK2V617F and exon 12
mutation positive polycythemia vera patients were collected
online from 15 haematology centres reporting epidemiologic,
clinical characteristics, diagnostic tools, therapeutic
interventions, thromboembolic complications, disease
transformations. Vascular events prior to and after diagnosis
were evaluated upon the Landolfi risk assessment scale.
RESULTS: 116 thromboembolic events were reported in 106 PV
patients prior to diagnosis and 152 occasions in 102 patients
during follow-up. The frequency of major arterial events were
significantly reduced (p<0.0001) and the minor venous events
were significantly elevated (p<0.0001) after the diagnosis.
Major hemorrhagic complications were found in 25 and
transformation in 26 cases. CONCLUSIONS: Our registry allows
to collect and evaluate the features of patients with
polycythemia vera. The Landolfi risk stratification was
proven to be useful. Based on evaluated data, accuracy of
diagnostic criteria and compliance to risk-adapted
therapeutic guidelines are needed. Orv Hetil. 2017; 158(23):
901-909. |
|
dc.relation.ispartof |
urn:issn:0030-6002 |
|
dc.title |
Philadelphia-negatív krónikus Myeloproliferativ Neoplasia Magyarországi Regiszter. Polycythaemia verás betegeink adatainak elemzése [Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients] |
|
dc.type |
Journal Article |
|
dc.date.updated |
2018-07-16T10:53:04Z |
|
dc.language.rfc3066 |
hu |
|
dc.identifier.mtmt |
3279789 |
|
dc.identifier.wos |
000403492900003 |
|
dc.identifier.pubmed |
28580853 |
|
dc.contributor.department |
SE/AOK/K/I. Sz. Belgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|